New Delhi, October 29 – In a significant move aimed at reducing cancer treatment costs, the National Pharmaceutical Pricing Authority (NPPA) has directed pharmaceutical companies to reduce the Maximum Retail Price (MRP) of three prominent anti-cancer drugs: Trastuzumab, Osimertinib, and Durvalumab. This directive follows the exemption of these drugs from customs duties and a reduction in Goods and Services Tax (GST), in line with the government’s ongoing commitment to making essential medicines affordable.
The Ministry of Chemicals and Fertilisers announced that the NPPA’s order aligns with measures outlined in the Union Budget 2024-25. Finance Minister Nirmala Sitharaman, while presenting the budget in Lok Sabha, proposed eliminating the 10% customs duty on these three drugs, a change officially implemented through a July 23 notification by the Department of Revenue, Ministry of Finance.
“By reducing these taxes, the government ensures that the benefit reaches consumers directly through lowered MRPs in the market,” stated the Ministry of Chemicals and Fertilisers. The NPPA has further mandated that all manufacturers of Trastuzumab, Osimertinib, and Durvalumab promptly adjust their price lists to reflect the reduced MRPs, sharing these updated prices with dealers, state drug controllers, and the NPPA.
Pharmaceutical companies have been instructed to provide revised price details to the NPPA and ensure transparency in passing on the cost benefits to consumers. The reduction in MRP is anticipated to make these essential cancer treatments more accessible, furthering the government’s mission to provide affordable healthcare solutions.
